Skip to main content
SpringerLink
Log in
Book cover

Frontiers in Cardiovascular Health pp 549–561Cite as

Prevention of Heart Failure—A Clinical Reality?

  • Chapter

  • 157 Accesses

Part of the book series: Progress in Experimental Cardiology ((PREC,volume 9))

Summary

Heart failure is a major public health problem and has substantial economic impact. Over the past several decades, the mortality for most cardiovascular diseases has declined. In contrast, the incidence of and mortality for heart failure have increased. The key steps to approach an epidemic are prevention and early intervention. Effective prevention of heart failure can be achieved by modification of risk factors, aggressive management of coronary heart disease and hypertension, and early treatment of left ventricular dysfunction.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liu P, Arnold JMO, Belenkie I, et al. 2001. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can J Card 17(Suppl E): 5E–25E.

    Google Scholar 

  2. Mair FS, Crowley TS. 1996. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 46:77.

    PubMed  CAS  Google Scholar 

  3. Ho KK, Pinsky JL, Kannel WB, Levy D. 1993. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 325:293–302.

    Google Scholar 

  4. Hunt SA, Baker DW, Chin MH, et al. 2001. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38(7):2101–2113.

    Article  PubMed  CAS  Google Scholar 

  5. Haldeman GA, Croft JB, Giles WH, Rashidee A. 1999. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am H J 137:352–60.

    Article  CAS  Google Scholar 

  6. Massie BM, Shah NB. 1997. Evolving trends in the epidemiology of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 133:703–712.

    Article  PubMed  CAS  Google Scholar 

  7. O’Connell JB, Bristow M. 1993. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 13:S107–112.

    Google Scholar 

  8. SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. JAMA 265:3255–3264.

    Article  Google Scholar 

  9. Systolic Hypertension in China (Syst-China) Collaborative Group. 1998. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens 16:1823–1829.

    Article  Google Scholar 

  10. Staessen JA, Fagard R, Thijs L, et al. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757–764.

    Article  PubMed  CAS  Google Scholar 

  11. Amery A, Birkenhager W, Brixko P, et al. 1985. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1:1349–54.

    Article  PubMed  CAS  Google Scholar 

  12. Coope J, Warrender TS. 1986. Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J 293:1145–1151.

    Article  CAS  Google Scholar 

  13. Dahlof B, Lindholm LH, Hansson L, et al. 1991. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281–1285.

    Article  PubMed  CAS  Google Scholar 

  14. ALLHAT Collaborative Research Group. 2000. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967–1975.

    Article  Google Scholar 

  15. Wachtell K, Bella JN, Rokkedal J, et al. 2002. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105:1071–1076.

    Article  PubMed  Google Scholar 

  16. Moser M, Hebert PR. 1996. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27(5):1214–1218.

    Article  PubMed  CAS  Google Scholar 

  17. Gheorghiade M, Bonow RO. 1998. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97:282–289.

    Article  PubMed  CAS  Google Scholar 

  18. The ACC/AHA Task Force on Practice Guidelines. 1999. ACC/AHA guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation 99:2829–2848.

    Article  Google Scholar 

  19. U.S. Carvedilol Heart Failure Study Group. 1996. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355.

    Article  Google Scholar 

  20. MERIT-HF Study Group. 1999. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/CX Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007.

    Article  Google Scholar 

  21. CIBIS-II Investigatiors and Committees. 1999. The Cardiac Insufficiency Study II: a randomized trial. Lancet 353:9–13.

    Article  Google Scholar 

  22. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of Carvedilol on survival in severe chronic heart failure. 2001. N Engl J Med 344:1651–1658.

    Article  Google Scholar 

  23. Norwegian Multicentre Study Group. 1981. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl Med 304:801–907.

    Article  Google Scholar 

  24. Beta-Blocker Heart Attack Trial Research Group. 1982. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250:2814–2819.

    Google Scholar 

  25. MIAMI Trial Research Group. 1985. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 6:199–226.

    Google Scholar 

  26. The CAPRICORN Investigators. 2001. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357: 1385–1390.

    Article  Google Scholar 

  27. Vantrimpont P, Rouleau JL, Wun CC, et al. 1997. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J Am Coll Cardiol 29(2):229–236.

    Article  PubMed  CAS  Google Scholar 

  28. Pfeffer MA, Braunwald E, Moye L, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 327:669–77.

    Article  PubMed  CAS  Google Scholar 

  29. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–828.

    Google Scholar 

  30. The Trandolapril Cardiac Evaluation (TRACE) Study Group. 1995. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670–1676.

    Article  Google Scholar 

  31. Flather M, Yusuf S, Kober L, et al. 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355:1575–1581.

    Article  PubMed  CAS  Google Scholar 

  32. Huckell VF, Bernstein V, Cairns JA, et al. 1997. Angiotensin-converting enzyme inhibition in myocardial infarction—Part 1: Clinical data. Can J Cardiol 13(2): 161–169.

    PubMed  CAS  Google Scholar 

  33. Sweberg K, Held P, Kjekshus J, et al. 1992. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678–684.

    Article  Google Scholar 

  34. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. 1994. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115–1122.

    Google Scholar 

  35. ISIS-4 Collaborative Group. 1995. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345:669–685.

    Article  Google Scholar 

  36. Chinese Cardiac Study Collaborative Group. 1995. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 345:686–687.

    Article  Google Scholar 

  37. ACE Inhibitor Myocardial Infarction Collaborative Group. 1998. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97:2202–2212.

    Article  Google Scholar 

  38. The SOLVD Investigators. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 327:685–691.

    Article  Google Scholar 

  39. Kannel WB, Ho K, Thom T. 1994. Changing epidemiological features of cardiac failure. Br Heart J 72(Suppl):S3–9.

    Article  PubMed  CAS  Google Scholar 

  40. Bonow RO, Carabello B, De Leon AC, et al. 1998. ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 32:1486–1588.

    Article  Google Scholar 

  41. Lin M, Chiang HT, Lin SL, et al. 1994. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol 24:1046–1053.

    Article  PubMed  CAS  Google Scholar 

  42. Schon HR, Dorn R, Barthel P, Schomig A. 1994. Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis 3:500–509.

    PubMed  CAS  Google Scholar 

  43. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. 1994. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 331:689–694.

    Article  PubMed  CAS  Google Scholar 

  44. Sole MJ, Liu P. 1993. Viral myocarditis: A paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 22(4) Suppl:99A–105A.

    Article  PubMed  CAS  Google Scholar 

  45. The Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153.

    Article  Google Scholar 

  46. The RENAAL Study Investigators. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869.

    Article  Google Scholar 

  47. The Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259.

    Article  Google Scholar 

  48. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, London Health Sciences Centre, Lawson Health Research Institute, 375 South Street, London, Canada, N6A 4G5

    Wilson Lee & Dr. J. Malcolm O. Arnold

  2. Department of Medicine, University of Western Ontario, Canada

    Wilson Lee & Dr. J. Malcolm O. Arnold

Authors
  1. Wilson Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. J. Malcolm O. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Malcolm O. Arnold .

Editor information

Editors and Affiliations

  1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Naranjan S. Dhalla PhD, MD (Hon), DSc (Hon) (Distinguished Professor and Director), H. Ivan Berkowitz MBA (Consultant) & Pawan K. Singal PhD, DSc (Professor) (Distinguished Professor and Director),  (Consultant) &  (Professor)

  2. Institute of Circulatory & Respiratory Health, Canadian Institutes of Health Research, Vancouver, Canada

    Arun Chockalingam PhD (Assistant Director) (Assistant Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lee, W., Arnold, J.M.O. (2003). Prevention of Heart Failure—A Clinical Reality?. In: Dhalla, N.S., Chockalingam, A., Berkowitz, H.I., Singal, P.K. (eds) Frontiers in Cardiovascular Health. Progress in Experimental Cardiology, vol 9. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0455-9_40

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0455-9_40

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5085-9

  • Online ISBN: 978-1-4615-0455-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation